TCM
RPTX

Tekla Capital Management’s Repare Therapeutics RPTX Stock Holding History

Tekla Capital Management’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$308K Hold
29,150
– – 0.01% 151
2023
Q1 		$287K Hold
29,150
– – 0.01% 160
2022
Q4 		$429K Hold
29,150
– – 0.02% 150
2022
Q3 		$354K Hold
29,150
– – 0.01% 155
2022
Q2 		$408K Hold
29,150
– – 0.02% 155
2022
Q1 		$415K Hold
29,150
– – 0.01% 163
2021
Q4 		$615K Buy
+29,150
New +$687K 0.02% 157

Other funds holding RPTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Tekla Capital Management's RPTX Position: Q2 2023 in Review

Tekla Capital Management held its Repare Therapeutics (RPTX) position steady in Q2 2023 at 29,150 shares worth $308K. The position accounts for 0.01% of the portfolio, ranked #151.

Tekla Capital Management first reported a position in RPTX in Q4 2021 and has held it in 7 quarters since. The position peaked at $615K in Q4 2021. 78 funds tracked by Wall St. Rank hold RPTX as of Q2 2023.

  • Tekla Capital Management held 29,150 shares of Repare Therapeutics worth $308K as of Q2 2023.
  • Tekla Capital Management left its Repare Therapeutics share count unchanged in Q2 2023.
  • Repare Therapeutics made up 0.01% of Tekla Capital Management's portfolio in Q2 2023, its #151 holding.
  • Tekla Capital Management first reported a position in Repare Therapeutics in Q4 2021 and has held it in 7 quarters since.
  • Tekla Capital Management's Repare Therapeutics position peaked at $615K in Q4 2021.
  • 78 funds tracked by Wall St. Rank held Repare Therapeutics as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.